Breaking News
EnGeneIC granted FDA Fast-Track Designation for Novel Armed Nanocell Drug Conjugate Pancreatic Cancer Therapeutic.
EnGeneIC has achieved a significant milestone with the granting of FDA “Fast-Track” designation for its pancreatic cancer therapeutic.
For more information about becoming a volunteer for the COVID-19 EDV™ Vaccine Trial contact our Clinical Trials Team.